Currently, two anti-BCMA-CAR T cell products, namely ide-cel and cilta-cel, have received clinical approval for treating relapsed/refractory multiple myeloma (RRMM), [12, 27], both of which are second-generation CARs (CAR2) that use the 4-1BB intracytoplasmic co-stimulatory domain. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.